

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
26 June 2025 (26.06.2025)



(10) International Publication Number  
**WO 2025/133635 A1**

(51) International Patent Classification:

A61K 48/00 (2006.01) C07K 16/24 (2006.01)  
C12N 15/63 (2006.01) C07K 16/28 (2006.01)  
C12N 15/86 (2006.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/GB2024/053193

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

20 December 2024 (20.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/614,082 22 December 2023 (22.12.2023) US  
63/614,146 22 December 2023 (22.12.2023) US

(71) Applicants: **THE UNIVERSITY OF BRISTOL** [GB/G-  
B]; Beacon House, Queens Road, Bristol BS8 1QU (GB).  
**CIRRUS THERAPEUTICS, INC.** [US/US]; 750 Main  
Street, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **CHAN, Ying Kai**; c/o Cirrus Therapeutics, Inc.,  
750 Main Street, Cambridge, Massachusetts 02139 (US).  
**COPLAND, David**; c/o The University of Bristol, Beacon  
House, Queens Road, Bristol BS8 1QU (GB). **DICK, An-  
drew**; c/o The University of Bristol, Beacon House, Queens  
Road, Bristol BS8 1QU (GB).

(74) Agent: **D YOUNG & CO LLP**; 3 Noble Street, London  
EC2V 7BQ (GB).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: THERAPIES FOR PREVENTING OR TREATING INFLAMMATORY EYE DISEASE

(57) Abstract: The present invention provides a combination comprising (a) a TNF inhibitor, or a polynucleotide comprising a nu-  
cleotide sequence encoding the same; and (b) a CD3 inhibitor, or a polynucleotide comprising a nucleotide sequence encoding the  
same, as a combined preparation for simultaneous, separate or sequential use in preventing or treating an inflammatory eye disease. The  
present invention also provides a vector comprising a nucleotide sequence encoding a CD3 inhibitor, wherein the nucleotide sequence  
encoding the CD3 inhibitor is operably linked to an inflammation-inducible promoter.

WO 2025/133635 A1